marketcaparena
Search

    PRPO

    Precipio, Inc.

    Company overview

    Market capitalization
    $43.16M
    Employees
    61
    Latest publication
    2026-09-29
    About Precipio, Inc.

    Precipio, Inc., a healthcare biotechnology company, provides cancer diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers HemeScreen, a suite of robust genetic diagnostic panels; and IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages. It offers biomarker testing and clinical project services to bio-pharma customers. Precipio, Inc. is based in New Haven, Connecticut.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Revenue7,021,000USD6,302,000USD7,974,000USD6,164,000USD5,654,000USD4,257,000USD5,450,000USD5,209,000USD
    Cost Of Revenue3,885,000USD3,577,000USD4,842,000USD3,159,000USD3,225,000USD2,117,000USD2,804,000USD2,932,000USD
    Gross Profit3,136,000USD2,725,000USD3,132,000USD3,005,000USD2,429,000USD2,140,000USD2,646,000USD2,277,000USD
    Total Operating Expenses3,735,000USD4,153,000USD2,590,000USD3,066,000USD3,253,000USD2,999,000USD2,982,000USD2,874,000USD
    Operating Income-599,000USD-1,428,000USD542,000USD-61,000USD-824,000USD-859,000USD-336,000USD-597,000USD
    Total Other Income Expense Net380,000USD-15,000USD-16,000USD-18,000USD898,000USD-25,000USD-29,000USD-29,000USD
    Income Before Tax-219,000USD-1,443,000USD526,000USD-79,000USD74,000USD-884,000USD-365,000USD-626,000USD
    Income Tax Expense0USD—————0USD-626,000USD
    Net Income-219,000USD-1,443,000USD526,000USD-79,000USD74,000USD-884,000USD-365,000USD-626,000USD
    Unclassified Operating Expenses—4,153,000USD1,801,000USD3,066,000USD2,464,000USD2,999,000USD-2,200,000USD2,874,000USD
    Interest Expense—15,000USD57,000USD9,000USD23,000USD25,000USD29,000USD29,000USD
    Net Interest Income—-15,000USD-16,000USD-9,000USD-23,000USD-25,000USD-29,000USD-29,000USD
    Tax Provision—0USD0USD0USD0USD0USD0USD0USD
    Net Income From Continuing Ops—-1,443,000USD526,000USD-79,000USD74,000USD-884,000USD-365,000USD-626,000USD
    Ebit—-1,428,000USD542,000USD-70,000USD97,000USD-859,000USD-336,000USD-597,000USD
    Ebitda—-971,000USD1,145,000USD240,000USD519,000USD-442,000USD46,000USD-216,000USD
    Depreciation And Amortization—457,000USD603,000USD310,000USD422,000USD417,000USD382,000USD381,000USD
    Reconciled Depreciation—457,000USD476,000USD437,000USD422,000USD417,000USD382,000USD381,000USD
    Selling General Administrative——789,000USD—789,000USD—2,882,000USD—
    Research Development——————2,300,000USD—
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Revenue24,049,000USD15,965,000USD15,197,000USD9,412,000USD8,849,000USD6,092,000USD3,127,000USD2,864,000USD
    Cost Of Revenue13,343,000USD8,406,000USD9,179,000USD6,902,000USD6,457,000USD4,942,000USD2,908,000USD2,639,000USD
    Gross Profit10,706,000USD7,559,000USD6,018,000USD2,510,000USD2,392,000USD1,150,000USD219,000USD225,000USD
    Unclassified Operating Expenses11,908,000USD-2,200,000USD-2,600,000USD——-2,100,000USD-1,100,000USD-1,100,000USD
    Total Operating Expenses11,908,000USD11,775,000USD13,638,000USD15,307,000USD12,005,000USD10,296,000USD11,213,000USD9,452,000USD
    Operating Income-1,202,000USD-4,216,000USD-7,620,000USD-12,797,000USD-9,613,000USD-9,146,000USD-10,994,000USD-13,912,000USD
    Interest Expense73,000USD74,000USD18,000USD12,000USD20,000USD470,000USD473,000USD1,597,000USD
    Net Interest Income-73,000USD-74,000USD-18,000USD-12,000USD-20,000USD-470,000USD-473,000USD-269,000USD
    Income Before Tax-363,000USD-4,290,000USD-5,853,000USD-12,178,000USD-8,517,000USD-10,598,000USD-13,313,000USD-15,973,000USD
    Tax Provision0USD0USD0USD0USD0USD-70,000USD-70,000USD-279,000USD
    Net Income-363,000USD-4,290,000USD-5,853,000USD-12,203,000USD-8,550,000USD-10,625,000USD-13,243,000USD-15,694,000USD
    Net Income From Continuing Ops-363,000USD-4,290,000USD-9,061,000USD-12,178,000USD-8,517,000USD-10,598,000USD-13,243,000USD-15,694,000USD
    Ebit-290,000USD-4,216,000USD-7,620,000USD-12,166,000USD-8,497,000USD-9,146,000USD-9,404,000USD-9,227,000USD
    Ebitda1,462,000USD-2,703,000USD-6,312,000USD-10,646,000USD-7,053,000USD-8,003,000USD-8,223,000USD-7,962,000USD
    Depreciation And Amortization1,752,000USD1,513,000USD1,308,000USD1,520,000USD1,444,000USD1,143,000USD1,181,000USD1,265,000USD
    Reconciled Depreciation1,752,000USD1,513,000USD1,519,000USD1,520,000USD1,444,000USD1,356,000USD1,412,000USD1,265,000USD
    Total Other Income Expense Net839,000USD-74,000USD1,767,000USD619,000USD1,096,000USD-1,452,000USD-2,319,000USD-2,061,000USD
    Research Development—2,300,000USD2,700,000USD1,700,000USD1,300,000USD2,200,000USD2,790,000USD1,100,000USD
    Selling General Administrative—11,675,000USD13,538,000USD13,507,000USD10,605,000USD10,196,000USD9,523,000USD9,452,000USD
    Income Tax Expense——1,349,105USD25,000USD33,000USD1,632,000USD-70,000USD-279,000USD
    Minority Interest——-7,000USD-25,000USD-13,000USD27,000USD27,000USD27,000USD
    Selling And Marketing Expenses———100,000USD100,000USD———
    Net Income Applicable To Common Shares————-8,530,000USD-10,625,000USD-13,243,000USD-19,916,000USD
    Non Operating Income Net Other—————-1,452,000USD-2,319,000USD-2,061,000USD
    Interest Income——————472,000USD1,531,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USDQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USD
    Total Assets21,321,000USD20,803,000USD21,317,000USD21,153,000USD18,816,000USD17,785,000USD16,996,000USD16,951,000USD
    Cash And Equivalents3,075,000USD———————
    Total Current Assets6,537,000USD5,932,000USD6,039,000USD5,668,000USD4,053,000USD3,278,000USD3,451,000USD3,255,000USD
    Other Current Assets407,000USD470,000USD-1,984,000USD618,000USD376,000USD460,000USD539,000USD591,000USD
    Other Non Current Assets54,000USD———————
    Total Liabilities6,563,000USD———————
    Total Current Liabilities3,701,000USD3,810,000USD3,752,000USD4,453,000USD4,353,000USD4,331,000USD4,271,000USD4,478,000USD
    Other Current Liabilities1,639,000USD———————
    Total Equity Including Noncontrolling Interest14,758,000USD———————
    Short Long Term Debt73,000USD30,000USD30,000USD30,000USD29,000USD147,000USD297,000USD444,000USD
    Long Term Debt252,000USD40,000USD47,000USD55,000USD62,000USD70,000USD77,000USD84,000USD
    Deferred Revenue364,000USD———————
    Net Receivables2,279,000USD1,988,000USD1,984,000USD1,957,000USD1,488,000USD976,000USD799,000USD1,021,000USD
    Inventory776,000USD870,000USD935,000USD788,000USD1,059,000USD825,000USD724,000USD590,000USD
    Property Plant Equipment Net3,411,000USD4,122,000USD4,292,000USD4,261,000USD3,309,000USD2,825,000USD1,631,000USD1,542,000USD
    Intangible Assets10,444,000USD10,682,000USD10,919,000USD11,157,000USD11,394,000USD11,631,000USD11,869,000USD12,106,000USD
    Accounts Payable972,000USD1,363,000USD1,131,000USD1,138,000USD1,164,000USD906,000USD618,000USD701,000USD
    Short Term Debt458,000USD666,000USD649,000USD611,000USD436,000USD477,000USD622,000USD752,000USD
    Common Stock18,000USD18,000USD18,000USD17,000USD15,000USD15,000USD15,000USD15,000USD
    Retained Earnings-104,465,000USD-104,246,000USD-102,803,000USD-103,329,000USD-103,250,000USD-103,324,000USD-102,440,000USD-102,075,000USD
    Total Liab—6,636,000USD6,756,000USD7,404,000USD6,528,000USD6,087,000USD4,902,000USD5,006,000USD
    Total Stockholder Equity—14,167,000USD14,561,000USD13,749,000USD12,288,000USD11,698,000USD12,094,000USD11,945,000USD
    Other Current Liab—1,660,000USD1,972,000USD2,428,000USD2,281,000USD2,464,000USD2,626,000USD2,591,000USD
    Capital Stock—18,000USD18,000USD17,000USD15,000USD15,000USD15,000USD15,000USD
    Cash—2,604,000USD6,039,000USD2,305,000USD1,130,000USD1,017,000USD1,389,000USD1,053,000USD
    Cash And Short Term Investments—2,604,000USD6,039,000USD2,305,000USD1,130,000USD1,017,000USD1,389,000USD1,053,000USD
    Current Deferred Revenue—121,000USD—276,000USD278,000USD289,000USD232,000USD282,000USD
    Net Debt—888,000USD-2,386,000USD1,257,000USD1,481,000USD1,216,000USD-136,000USD227,000USD
    Short Long Term Debt Total—3,492,000USD3,653,000USD3,562,000USD2,611,000USD2,233,000USD1,253,000USD1,280,000USD
    Property Plant Equipment Gross—4,122,000USD6,158,000USD4,261,000USD3,309,000USD2,825,000USD3,258,000USD1,542,000USD
    Common Stock Shares Outstanding—1,783,080shares1,605,080shares1,637,486shares1,602,438shares1,502,652shares1,493,639shares1,480,217shares
    Non Current Assets Total—14,871,000USD15,278,000USD15,485,000USD14,763,000USD14,507,000USD13,545,000USD13,696,000USD
    Non Current Liabilities Total—2,826,000USD3,004,000USD2,951,000USD2,175,000USD1,756,000USD631,000USD528,000USD
    Non Currrent Assets Other—67,000USD4,359,000USD67,000USD60,000USD51,000USD45,000USD48,000USD
    Net Working Capital—2,122,000USD2,287,000USD1,215,000USD-300,000USD-1,053,000USD-820,000USD-1,223,000USD
    Unclassified Non Current Liabilities—2,786,000USD2,957,000USD2,896,000USD2,113,000USD1,686,000USD——
    Unclassified Equity—118,377,000USD117,328,000USD117,044,000USD115,508,000USD114,992,000USD114,504,000USD113,990,000USD
    Unclassified Current Assets——-2,919,000USD—————
    Unclassified Non Current Assets——-4,292,000USD—————
    SourceDisclosureDeterministicFinalLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Total Assets21,317,000USD16,996,000USD18,101,000USD21,504,000USD30,439,000USD20,713,000USD19,511,000USD21,605,000USD
    Intangible Assets10,919,000USD11,869,000USD12,818,000USD13,768,000USD14,717,000USD15,667,000USD16,658,000USD19,291,000USD
    Other Current Assets-2,919,000USD539,000USD495,000USD521,000USD549,000USD324,000USD272,000USD525,000USD
    Total Liab6,756,000USD4,902,000USD3,672,000USD5,137,000USD5,835,000USD6,551,000USD6,306,000USD15,482,000USD
    Total Stockholder Equity14,561,000USD12,094,000USD14,429,000USD16,302,000USD24,564,000USD14,135,000USD13,205,000USD6,123,000USD
    Other Current Liab1,972,000USD2,626,000USD1,537,000USD1,493,000USD1,770,000USD1,610,000USD1,639,000USD3,850,000USD
    Common Stock18,000USD15,000USD14,000USD228,000USD227,000USD176,000USD79,000USD345,000USD
    Capital Stock18,000USD15,000USD14,000USD228,000USD227,000USD176,000USD79,000USD345,000USD
    Retained Earnings-102,803,000USD-102,440,000USD-98,150,000USD-92,297,000USD-80,094,000USD-71,564,000USD-60,939,000USD-47,696,000USD
    Cash6,039,000USD1,389,000USD1,502,000USD3,445,000USD11,668,000USD2,656,000USD848,000USD381,000USD
    Cash And Short Term Investments6,039,000USD1,389,000USD1,502,000USD3,445,000USD11,668,000USD2,656,000USD848,000USD381,000USD
    Total Current Assets6,039,000USD3,451,000USD3,682,000USD5,710,000USD13,478,000USD4,204,000USD1,878,000USD1,793,000USD
    Total Current Liabilities3,752,000USD4,271,000USD3,141,000USD4,361,000USD4,213,000USD4,656,000USD4,334,000USD13,765,000USD
    Net Debt-2,386,000USD-136,000USD-386,000USD-2,053,000USD-10,238,000USD-1,165,000USD510,000USD4,724,000USD
    Short Term Debt649,000USD622,000USD585,000USD616,000USD414,000USD921,000USD724,000USD4,697,000USD
    Short Long Term Debt30,000USD297,000USD235,000USD255,000USD26,000USD648,000USD463,000USD4,640,000USD
    Short Long Term Debt Total3,653,000USD1,253,000USD1,116,000USD1,392,000USD1,430,000USD1,491,000USD1,358,000USD5,105,000USD
    Long Term Debt47,000USD77,000USD106,000USD134,000USD160,000USD362,000USD198,000USD253,000USD
    Net Receivables1,984,000USD799,000USD1,301,000USD1,036,000USD697,000USD874,000USD574,000USD690,000USD
    Inventory935,000USD724,000USD384,000USD708,000USD564,000USD350,000USD184,000USD197,000USD
    Accounts Payable1,131,000USD618,000USD622,000USD2,042,000USD1,863,000USD1,693,000USD1,936,000USD5,169,000USD
    Property Plant Equipment Net4,292,000USD1,631,000USD1,525,000USD1,897,000USD2,065,000USD787,000USD950,000USD496,000USD
    Property Plant Equipment Gross6,158,000USD3,258,000USD2,902,000USD2,999,000USD2,898,000USD787,000USD950,000USD496,000USD
    Common Stock Shares Outstanding1,605,080shares1,465,518shares1,297,851shares1,137,573shares1,054,909shares823,853shares284,757shares72,055shares
    Non Current Assets Total15,278,000USD13,545,000USD14,419,000USD15,794,000USD16,961,000USD16,509,000USD17,633,000USD19,812,000USD
    Non Current Liabilities Total3,004,000USD631,000USD531,000USD776,000USD1,622,000USD1,895,000USD1,972,000USD1,717,000USD
    Non Currrent Assets Other4,359,000USD45,000USD76,000USD129,000USD179,000USD55,000USD25,000USD25,000USD
    Net Working Capital2,287,000USD-820,000USD541,000USD1,349,000USD9,265,000USD-452,000USD-2,456,000USD-11,972,000USD
    Unclassified Current Assets-2,919,000USD———————
    Unclassified Non Current Assets-4,292,000USD———————
    Unclassified Non Current Liabilities2,957,000USD————-1,325,000USD-1,338,000USD—
    Unclassified Equity117,328,000USD114,504,000USD112,551,000USD108,143,000USD104,204,000USD85,347,000USD74,777,000USD53,782,000USD
    Other Assets—1USD1USD—179,000USD390,000USD25,000USD25,000USD
    Current Deferred Revenue—232,000USD110,000USD119,000USD18,000USD6,000USD35,000USD49,000USD
    Accumulated Other Comprehensive Income——0USD———-791,000USD-653,000USD
    Other Liab————606,000USD1,325,000USD1,338,000USD1,309,000USD
    Net Tangible Assets————9,847,000USD-1,532,000USD-3,453,000USD6,123,000USD
    Non Current Liabilities Other—————1,533,000USD1,774,000USD45,000USD
    Good Will———————0USD
    Unclassified Current Liabilities———————-4,640,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-06-30 · USD
    Depreciation572,000USD
    Stock Based Compensation1,760,000USD
    Change To Account Receivables-545,000USD
    Change To Inventory159,000USD
    Change To Liabilities-210,000USD
    Change In Working Capital-388,000USD
    Operating Cash Flow724,000USD
    Capital Expenditures-182,000USD
    Investing Cash Flow-182,000USD
    Net Debt Issuance-114,000USD
    Net Common Stock Issuance-29,000USD
    Unclassified Financing Cash Flow25,000USD
    Financing Cash Flow-118,000USD
    Change In Cash424,000USD
    End Cash Flow3,075,000USD
    SourceDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ1 20262026-03-31 · USDQ4 20252025-12-31 · USDQ3 20252025-09-30 · USDQ2 20252025-06-30 · USDQ1 20252025-03-31 · USDQ4 20242024-12-31 · USDQ3 20242024-09-30 · USDQ2 20242024-06-30 · USD
    Net Income-1,443,000USD526,000USD-79,000USD74,000USD-884,000USD-365,000USD-626,000USD-1,220,000USD
    Depreciation396,000USD495,000USD437,000USD422,000USD417,000USD382,000USD381,000USD372,000USD
    Stock Based Compensation993,000USD105,000USD232,000USD449,000USD423,000USD823,000USD147,000USD299,000USD
    Other Non Cash Items365,000USD165,000USD149,000USD-93,000USD16,000USD-425,000USD1,501,000USD281,000USD
    Change To Account Receivables-254,000USD-149,000USD-587,000USD-487,000USD-139,000USD341,000USD15,000USD-230,000USD
    Change To Inventory65,000USD-147,000USD271,000USD-234,000USD-101,000USD-134,000USD63,000USD-121,000USD
    Change In Working Capital-247,000USD-925,000USD-729,000USD-499,000USD-16,000USD150,000USD-1,362,000USD768,000USD
    Total Cash From Operating Activities64,000USD366,000USD10,000USD353,000USD-44,000USD565,000USD41,000USD500,000USD
    Capital Expenditures-50,000USD-75,000USD-54,000USD-59,000USD-138,000USD-44,000USD-109,000USD-70,000USD
    Free Cash Flow14,000USD291,000USD-44,000USD294,000USD-182,000USD521,000USD-68,000USD430,000USD
    Total Cashflows From Investing Activities-50,000USD-75,000USD-54,000USD-59,000USD-138,000USD-44,000USD-109,000USD-70,000USD
    Net Borrowings-64,000USD-65,000USD-41,000USD-181,000USD-190,000USD-185,000USD-158,000USD—
    Total Cash From Financing Activities-61,000USD55,000USD1,219,000USD-181,000USD-190,000USD-185,000USD-158,000USD73,000USD
    Change In Cash-47,000USD346,000USD1,175,000USD113,000USD-372,000USD336,000USD-226,000USD503,000USD
    Begin Period Cash Flow2,651,000USD2,305,000USD1,130,000USD1,017,000USD1,389,000USD1,053,000USD1,279,000USD776,000USD
    End Period Cash Flow2,604,000USD2,651,000USD2,305,000USD1,130,000USD1,017,000USD1,389,000USD1,053,000USD1,279,000USD
    Other Cashflows From Financing Activities-61,000USD55,000USD1,219,000USD—-157,000USD67,000USD-109,000USD11,000USD
    Issuance Of Capital Stock—0USD0USD0USD0USD0USD0USD11,000USD
    Investments——-54,000USD-59,000USD-138,000USD-44,000USD-109,000USD-70,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-12-31 · USDFY 20242024-12-31 · USDFY 20232023-12-31 · USDFY 20222022-12-31 · USDFY 20212021-12-31 · USDFY 20202020-12-31 · USDFY 20192019-12-31 · USDFY 20182018-12-31 · USD
    Net Income-363,000USD-4,290,000USD-5,853,000USD-12,178,000USD-8,517,000USD-10,598,000USD-13,243,000USD-15,694,000USD
    Depreciation1,564,000USD1,513,000USD1,517,000USD1,520,000USD1,444,000USD1,356,000USD1,412,000USD1,265,000USD
    Stock Based Compensation1,209,000USD1,877,000USD1,735,000USD3,801,000USD2,029,000USD703,000USD668,000USD529,000USD
    Other Non Cash Items444,000USD69,000USD-1,564,000USD-221,000USD-1,138,000USD2,739,000USD810,000USD1,044,000USD
    Change To Account Receivables-1,362,000USD438,000USD-483,000USD-745,000USD327,000USD-1,639,000USD-850,000USD-541,000USD
    Change To Inventory-211,000USD-340,000USD324,000USD-144,000USD-214,000USD-166,000USD13,000USD-36,000USD
    Change In Working Capital-2,169,000USD1,270,000USD606,000USD-643,000USD-395,000USD-1,634,000USD-2,491,000USD109,000USD
    Total Cash From Operating Activities685,000USD439,000USD-3,559,000USD-7,721,000USD-6,577,000USD-7,434,000USD-9,141,000USD-6,754,000USD
    Capital Expenditures-326,000USD-223,000USD-126,000USD-277,000USD-682,000USD-151,000USD-55,000USD-97,000USD
    Free Cash Flow359,000USD216,000USD-3,685,000USD-7,998,000USD-7,259,000USD-7,585,000USD-9,196,000USD-6,851,000USD
    Total Cashflows From Investing Activities-326,000USD-223,000USD-126,000USD-277,000USD-682,000USD-96,000USD-55,000USD-97,000USD
    Net Borrowings-477,000USD-407,000USD-503,000USD-365,000USD-170,000USD409,000USD1,507,000USD3,532,000USD
    Total Cash From Financing Activities903,000USD-329,000USD1,742,000USD-225,000USD16,271,000USD9,338,000USD9,663,000USD6,811,000USD
    Issuance Of Capital Stock0USD78,000USD2,245,000USD129,000USD16,207,000USD8,929,000USD6,628,000USD2,008,000USD
    Change In Cash1,262,000USD-113,000USD-1,943,000USD-8,223,000USD9,012,000USD1,808,000USD467,000USD-40,000USD
    Begin Period Cash Flow1,389,000USD1,502,000USD3,445,000USD11,668,000USD2,656,000USD848,000USD381,000USD421,000USD
    End Period Cash Flow2,651,000USD1,389,000USD1,502,000USD3,445,000USD11,668,000USD2,656,000USD848,000USD381,000USD
    Other Cashflows From Financing Activities903,000USD-407,000USD-126,000USD11,000USD273,000USD-96,000USD7,330,000USD1,133,000USD
    Investments—-223,000USD-129,000USD-277,000USD-682,000USD-96,000USD-55,000USD-97,000USD
    Change To Liabilities————112,000USD-243,000USD-1,858,000USD559,000USD
    Sale Purchase Of Stock—————8,929,000USD-1,000USD3,279,000USD
    Cash And Cash Equivalents Changes—————1,808,000USD467,000USD-40,000USD
    Other Cashflows From Investing Activities—————55,000USD——
    Dividends Paid——————-3,725,000USD—
    Unclassified Operating Cash Flow——————3,703,000USD5,993,000USD
    Unclassified Financing Cash Flow——————4,552,000USD-1,133,000USD
    SourceLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacyLegacy providerLegacy

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q1 2026Quarterly · 2026-03-31ProductProduct659,000USD0001104659-26-061188
    Q1 2026Quarterly · 2026-03-31ProductService Revenue Net14,708,000USD0001104659-26-061188
    Q4 2025Quarterly · 2025-12-31ProductProduct742,000USDLegacy provider
    Q4 2025Quarterly · 2025-12-31ProductService Revenue Net14,511,000USDLegacy provider
    FY 2025Yearly · 2025-12-31ProductProduct2,741,000USD0001104659-26-036878
    FY 2025Yearly · 2025-12-31ProductService Revenue Net50,751,000USD0001104659-26-036878
    Q3 2025Quarterly · 2025-09-30ProductProduct721,000USD0001104659-25-112601
    Q3 2025Quarterly · 2025-09-30ProductService Revenue Net14,458,000USD0001104659-25-112601
    Q2 2025Quarterly · 2025-06-30ProductProduct624,000USD0001558370-25-011390
    Q2 2025Quarterly · 2025-06-30ProductService Revenue Net11,712,000USD0001558370-25-011390
    Q1 2025Quarterly · 2025-03-31ProductProduct654,000USD0001104659-26-061188
    Q1 2025Quarterly · 2025-03-31ProductService Revenue Net10,070,000USD0001104659-26-061188
    Q4 2024Quarterly · 2024-12-31ProductProduct675,000USDLegacy provider
    Q4 2024Quarterly · 2024-12-31ProductService Revenue Net11,355,000USDLegacy provider
    FY 2024Yearly · 2024-12-31ProductProduct2,611,000USD0001104659-26-036878
    FY 2024Yearly · 2024-12-31ProductService Revenue Net39,173,000USD0001104659-26-036878
    Q3 2024Quarterly · 2024-09-30ProductProduct681,000USD0001104659-25-112601
    Q3 2024Quarterly · 2024-09-30ProductService Revenue Net11,212,000USD0001104659-25-112601
    Q2 2024Quarterly · 2024-06-30ProductProduct598,000USD0001558370-25-011390
    Q2 2024Quarterly · 2024-06-30ProductService Revenue Net9,522,000USD0001558370-25-011390
    FY 2023Yearly · 2023-12-31ProductProduct3,019,000USD0001558370-25-003817
    FY 2023Yearly · 2023-12-31ProductService Revenue Net26,490,000USD0001558370-25-003817
    FY 2022Yearly · 2022-12-31ProductOther1,402,000USD0001558370-24-004365
    FY 2022Yearly · 2022-12-31ProductService Revenue Net18,888,000USD0001558370-24-004365
    FY 2021Yearly · 2021-12-31ProductOther914,000USD0001558370-23-005076
    FY 2021Yearly · 2021-12-31ProductService Revenue Net16,768,000USD0001558370-23-005076
    FY 2020Yearly · 2020-12-31ProductOther220,000USD0001558370-22-004774
    FY 2020Yearly · 2020-12-31ProductService Revenue Net15,663,000USD0001558370-22-004774
    FY 2019Yearly · 2019-12-31ProductBiomarker Testing And Clinical Project Services595,000USD0001558370-20-003247
    FY 2019Yearly · 2019-12-31ProductDiagnostic Testing3,456,000USD0001558370-20-003247
    FY 2019Yearly · 2019-12-31ProductOther44,000USD0001558370-20-003247
    FY 2019Yearly · 2019-12-31ProductOther Party44,000USD0001558370-20-003247
    FY 2019Yearly · 2019-12-31ProductService Revenue Net4,051,000USD0001558370-20-003247
    FY 2018Yearly · 2018-12-31ProductOther Party113,000USD0001558370-20-003247
    FY 2018Yearly · 2018-12-31ProductService Revenue Net4,788,000USD0001558370-20-003247
    Q2 2015Quarterly · 2015-06-30GeographyAll Other Countries950,000USD0001043961-15-000014
    Q2 2015Quarterly · 2015-06-30GeographyItaly193,000USD0001043961-15-000014
    Q2 2015Quarterly · 2015-06-30GeographyUnited States5,897,000USD0001043961-15-000014
    Q2 2015Quarterly · 2015-06-30SegmentClinical Laboratories4,839,000USD0001043961-15-000014
    Q2 2015Quarterly · 2015-06-30SegmentGenetic Assaysand Platforms2,201,000USD0001043961-15-000014
    Q1 2015Quarterly · 2015-03-31GeographyAll Other Countries827,000USD0001043961-15-000011
    Q1 2015Quarterly · 2015-03-31GeographyItaly177,000USD0001043961-15-000011
    Q1 2015Quarterly · 2015-03-31GeographyUnited States5,509,000USD0001043961-15-000011
    Q1 2015Quarterly · 2015-03-31SegmentClinical Laboratories4,871,000USD0001043961-15-000011
    Q1 2015Quarterly · 2015-03-31SegmentGenetic Assaysand Platforms1,642,000USD0001043961-15-000011
    Q4 2014Quarterly · 2014-12-31SegmentClinical Laboratories4,926,000USDLegacy provider
    Q4 2014Quarterly · 2014-12-31SegmentGenetic Assaysand Platforms2,770,000USDLegacy provider
    FY 2014Yearly · 2014-12-31GeographyAll Other Countries3,892,000USD0001043961-15-000004
    FY 2014Yearly · 2014-12-31GeographyItaly1,258,000USD0001043961-15-000004
    FY 2014Yearly · 2014-12-31GeographyUnited Kingdom881,000USD0001043961-15-000004
    FY 2014Yearly · 2014-12-31GeographyUnited States21,052,000USD0001043961-15-000004
    FY 2014Yearly · 2014-12-31SegmentClinical Laboratories16,520,000USD0001043961-15-000004
    FY 2014Yearly · 2014-12-31SegmentGenetic Assaysand Platforms10,563,000USD0001043961-15-000004
    Q3 2014Quarterly · 2014-09-30GeographyAll Other Countries969,000USD0001043961-14-000012
    Q3 2014Quarterly · 2014-09-30GeographyItaly301,000USD0001043961-14-000012
    Q3 2014Quarterly · 2014-09-30GeographyUnited States5,102,000USD0001043961-14-000012
    Q3 2014Quarterly · 2014-09-30SegmentClinical Laboratories4,063,000USD0001043961-14-000012
    Q3 2014Quarterly · 2014-09-30SegmentGenetic Assaysand Platforms2,309,000USD0001043961-14-000012
    Q2 2014Quarterly · 2014-06-30GeographyAll Other Countries1,557,000USD0001043961-15-000014
    Q2 2014Quarterly · 2014-06-30GeographyItaly337,000USD0001043961-15-000014
    Q2 2014Quarterly · 2014-06-30GeographyUnited States4,870,000USD0001043961-15-000014
    Q2 2014Quarterly · 2014-06-30SegmentClinical Laboratories3,843,000USD0001043961-15-000014
    Q2 2014Quarterly · 2014-06-30SegmentGenetic Assaysand Platforms2,921,000USD0001043961-15-000014
    Q1 2014Quarterly · 2014-03-31GeographyAll Other Countries1,103,000USD0001043961-15-000011
    Q1 2014Quarterly · 2014-03-31GeographyItaly385,000USD0001043961-15-000011
    Q1 2014Quarterly · 2014-03-31GeographyUnited States4,763,000USD0001043961-15-000011
    Q1 2014Quarterly · 2014-03-31SegmentClinical Laboratories3,688,000USD0001043961-15-000011
    Q1 2014Quarterly · 2014-03-31SegmentGenetic Assaysand Platforms2,563,000USD0001043961-15-000011
    FY 2013Yearly · 2013-12-31GeographyAll Other Countries5,147,000USD0001043961-15-000004
    FY 2013Yearly · 2013-12-31GeographyItaly1,530,000USD0001043961-15-000004
    FY 2013Yearly · 2013-12-31GeographyUnited Kingdom748,000USD0001043961-15-000004
    FY 2013Yearly · 2013-12-31GeographyUnited States20,119,000USD0001043961-15-000004
    FY 2013Yearly · 2013-12-31SegmentClinical Laboratories15,391,000USD0001043961-15-000004
    FY 2013Yearly · 2013-12-31SegmentGenetic Assaysand Platforms12,153,000USD0001043961-15-000004
    Q3 2013Quarterly · 2013-09-30GeographyAll Other Countries1,153,000USD0001043961-14-000012
    Q3 2013Quarterly · 2013-09-30GeographyItaly398,000USD0001043961-14-000012
    Q3 2013Quarterly · 2013-09-30GeographyUnited States5,095,000USD0001043961-14-000012
    Q3 2013Quarterly · 2013-09-30SegmentClinical Laboratories4,112,000USD0001043961-14-000012
    Q3 2013Quarterly · 2013-09-30SegmentGenetic Assaysand Platforms2,534,000USD0001043961-14-000012
    FY 2012Yearly · 2012-12-31GeographyAll Other Countries4,526,000USD0001043961-15-000004
    FY 2012Yearly · 2012-12-31GeographyItaly2,524,000USD0001043961-15-000004
    FY 2012Yearly · 2012-12-31GeographyUnited Kingdom1,703,000USD0001043961-15-000004
    FY 2012Yearly · 2012-12-31GeographyUnited States22,727,000USD0001043961-15-000004
    FY 2012Yearly · 2012-12-31SegmentClinical Laboratories19,329,000USD0001043961-15-000004
    FY 2012Yearly · 2012-12-31SegmentGenetic Assaysand Platforms12,151,000USD0001043961-15-000004

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.